Reproducibility of the Bath Ankylosing Spondylitis indices of Disease Activity (BASDAI), functional status (BASFI) and overall well-being (BAS-G) in anti-tumour necrosis factor-treated spondyloarthropathy patients

Clinical Rheumatology

Volumn 29, Issue 8, 2010, Pages 849-854

  Madsen, Ole R ^a   Rytter, Anne ^b   Hansen, Lonnie B ^b   Suetta, Charlotte ^b,c   Egsmose, Charlotte ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Agreement; Ankylosing Spondylitis; BAS G; BASDAI; BASFI; Measurement error; Reliability; Reproducibility

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING APONDYLITIS GLOBAL SCORE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTION INDEX; CLINICAL ARTICLE; CONSTRUCT VALIDITY; DISEASE ACTIVITY; FEMALE; FUNCTIONAL STATUS; HUMAN; MALE; MEASUREMENT ERROR; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PAIN ASSESSMENT; PRIORITY JOURNAL; REPRODUCIBILITY; SPONDYLOARTHROPATHY; WELLBEING; ANTAGONISTS AND INHIBITORS; DENMARK; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; DENMARK; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77956264292     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-010-1407-5     Document Type: Article

References (31)

1. Zochling J, Braun J (2007) Assessments in ankylosing spondylitis. Best Pract Res Clin Rheumatol 21:699-712
2. Ward MM (1998) Quality of life in patients with ankylosing spondylitis. Rheum Dis Clin North Am 24:815-827
3. Garrett S, Jenkinson T, Keenedy G et al (1994) A new approach to evaluate to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1:2286-2291
4. Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281-2285
5. Jones SD, Steiner A, Garrett SL et al (1996) The Bath ankylosing spondylitis patient global score (BAS-G). Br J Rheumatol 35:66-71
6. Zochling J, van der Heijde D, Burgos-Vargas R et al (2006) ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65:442-452
7. Sidiropoulos PI, Hatemi G, Song IH et al (2008) Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatol (Oxf) 47:355-361
8. Hetland ML (2005) DANBIO: a nationwide registry of biological therapies in Denmark. Clin Exp Rheumatol 23(5 suppl 39):S205-S207
9. Altman DG, Bland JM (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307-310
10. Cronstedt H, Waldner A, Stenström CH (1999) The Swedish version of the Bath ankylosing spondylitis functional index. Reliability and validity. Scand J Rheumatol Suppl 111:1-9
11. Waldner A, Cronstedt H, Stenström CH (1999) The Swedish version of the Bath Ankylosing Spondylitis Disease Activity Index. Reliability and validity. Scand J Rheumatol Suppl 111:10
12. Pedersen OB, Hansen GO, Svendsen AJ et al (2007) Adaptation of the Bath measures on disease activity and function in ankylosing spondylitis into Danish. Scand J Rheumatol 36:22-27
13. Udrea G, Ciobanu C, Mihai C et al (2004) Evaluation of the Romanian version of the Bath Ankylosing Spondylitis Functional Index (BASFI) in patients with spondyloarthropathies. Rom J Intern Med 42:199-209
14. Accoc Y, Karatepe AG, Akar S et al (2005) A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity. Rheumatol Int 25:280-284
15. Karatepe AG, Akkoc Y, Akar S et al (2005) The Turkish versions of the Bath Ankylosing Spondylitis and Dougados Functional Indices: reliability and validity. Rheumatol Int 25:612-618
16. Chatzitheodorou D, Kabitsis C, Papadopoulos NG et al (2007) Evaluation of the Greek version of the Bath Ankylosing Spondylitis Functional Index: reliability, validity, and factor analysis. Clin Exp Rheumatol 25:571-576
17. El Miedany Y, Youssef S, Mehenna A (2008) Defining disease status in ankylosing spondylitis: validation and cross-cultural adaptation of the Arabic Bath Ankylosing Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and the Bath Ankylosing Spondylitis Global Score (BASG). Clin Rheumatol 27:605-612
18. Cardiel MH, Londono JD, Gutierrez E et al (2003) Translation, cross-cultural adaptation, and validation of the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease activity Index (BASDAI) and the Dougados Functional Index (DFI) in a Spanish speaking population with spondyloarthropathies. Clin Exp Rheumatol 21:451-458
19. Heikkila S, Viitanen JV, Kautianen H et al (2000) Evaluation of the Finnish versions of the functional indices BASFI and DFI in spondyloarthropathy. Clin Rheumatol 19:464-469
20. Claudepierre P, Sibilia J, Goupille P et al (1997) Evaluation of a French version of the Bath Ankylosing Spondylitis Disease Activity Index in patients with spondyloarthropathy. J Rheumatol 24:1954-1958
21. Ozer HT, Sarpel T, Gulek B (2005) The Turkish version of the Bath Ankylosing Spondylitis Functional Index: reliability and validity. Clin Rheumatol 24:123-128
22. Wei JC, Wong RH, Huang JH et al (2007) Evaluation of internal consistency and re-test reliability of Bath ankylosing spondylitis indices in a large cohort of adult and juvenile spondylitis patients in Taiwan. Clin Rheumatol 26:1685-1691
23. Dougados M, van der Linden S, Juhlin R et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34:1218-1227
24. Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 27:361-368
25. Jenkinson TR, Mallorie PA, Whitelock HC (1994) Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 21:694-698
26. Madsen OR, Hansen LB, Rytter A, Suetta C, Egsmose C (2009) The Bath metrology index as assessed by a trained and an untrained rater in patients with spondylarthropathy: a study of intra-and inter-rater agreements. Clin Rheumatol 28:35-40
27. Bland JM, Altman DG (1996) Statistics notes: measurement error. BMJ 313:714
28. Glüer CC, Blake G, Lu Y (1995) Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. Osteoporosis Int 5:262-270
29. Bland JM, Altman DG (1996) Statistics notes: measurement error and correlation coefficients. BMJ 313:41-42
30. van der Heijde D, Dijkmans B, Geusens P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582-591
31. van der Heijde D, Schiff MH, Sieper J et al (2009) Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 68:922-929